About Trimeris
Trimeris is a company based in Durham (United States) founded in 1993 was acquired by Synageva in June 2011. Trimeris operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter Durham, United States
- Stage Public
- SectorsHealthcare
- Website trimeris.com
- Acquired by Synageva (Jun 2011)
- Legal Name Trimeris, Inc.
Funding Insights of Trimeris
- Total Rounds 3
- Last Round Post-IPO — $102.4M
- First Round $43.4M
(May 2001)
All 3 funding rounds of Trimeris with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2002 | $102.4M | Post-IPO | – | – | – |
| Jan 2002 | $41M | Post-IPO | – | – | – |
| May 2001 | $43.4M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Trimeris
Trimeris has secured backing from 1 investor. Prominent investors backing the company include Synageva.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Enzyme replacement therapies for rare diseases are developed. | 1996 | synageva.com | Lexington, United States |
Investor details for Trimeris
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Trimeris
1 people are tracked at Trimeris (1 in leadership).
| Name | Role | Group |
|---|---|---|
Steven D Skolsky | CEO | Leadership |
Complete people profiles for Trimeris
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Trimeris
5 dated milestones of Trimeris across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Trimeris is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $43.4M.
- Funding Latest funding round, Post-IPO, of $102.4M.
- Exit Acquired by Synageva.
Competitors of Trimeris
Trimeris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering | |
| hookipapharma.com | 2011 | Vienna, Austria | $133.72M | – | Developer of immunotherapies for the treatment of infectious diseases and cancer | |
| briibio.com | 2018 | San Francisco, United States | $415M | 68 | Developer of biologics to treat hepatitis B infection | |
| vbivaccines.com | 2001 | Cambridge, United States | $65.07M | 13 | VBI Vaccines is engaged in developing vaccines and immunotherapeutics. | |
| visterrainc.com | 2007 | Cambridge, United States | $116.17M | 79 | Developer of monoclonal antibodies against infectious diseases | |
| clearlabs.com | 2014 | Menlo Park, United States | $171.09M | 55 | Food safety technologies are provided for pathogen identification. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. |
Detailed competitors of Trimeris
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Trimeris
Websites that share an audience with Trimeris (trimeris.com).
Websites whose visitors overlap most with Trimeris. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oncolys.com | 100% | 32.2K | #685,223 | View details | |
| sutrobio.com | 100% | 12.4K | #2,081,214 | View details | |
| canfite.com | 100% | 4.5K | #4,278,330 | View details | |
| redhillbio.com | 100% | 5.7K | #4,631,827 | View details | |
| aryogen.com | 62% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Trimeris
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to Trimeris
10 companies that operate in the same segment as Trimeris (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Trimeris
Trimeris was founded in 1993 and raised its 1st funding round 8 years after it was founded.
Trimeris is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Steven D Skolsky is the current CEO of Trimeris.
Trimeris was founded in 1993 as a biopharmaceutical company based in Durham, United States, with a focus on fusion inhibitor drugs targeting viral infections. Collaboration with Roche led to the FDA approval of Fuzeon, a peptide analog derived from HIV gp41, for HIV treatment. Additional efforts included the development of TRI-1144 to enhance HIV suppression and resistance barriers. The company was acquired by Synageva Pharmaceuticals in 2011.
Trimeris's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Trimeris has 1 investor. Key investors include Synageva.
Trimeris operates through Trimeris, Inc..
Yes. Trimeris was acquired by Synageva in June 2011.